Delcath Systems, Inc.
1100 Summer Street, 3rd Floor
391 articles with Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Company’s Board of Directors has authorized a 1-for-700 reverse stock split of the Company’s common stock.
Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that Dr. Jennifer Simpson, Ph.D., Chief Executive Officer and Ms. Barbra Keck, Chief Financial Officer, will present at the 12th Annual LD Micro Main Event investor conference at 1 p.m. PT (4 p.m. ET) on Tuesday, December 10, 2019.
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Reverse Stock Split reported on October 21, 2019 will be postponed per a subsequent notification received from FINRA after-market that they have decided to continue their review.
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock split of the Company’s common stock at a ratio of 1-for-100.
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European RadiologyPHP Therapy in ICC Treatment Shows Promise in Retrospective Analysis
Delcath Systems, Inc. announces that results of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been published in the journal European Radiology. The study is the first analysis on the use of Delcath’s PHP® Therapy for the treatment of ICC.
Percutaneous Hepatic Perfusion Therapy with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver.
On December 28, 2017, Delcath entered into exchange agreements with two institutional investors pursuant to which those investors were issued, in exchange for satisfaction in full of those notes.
The modification agreement revises the FOCUS trial’s eligibility criteria.
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
Patients in the study were treated at the two centers between December 2008 and October 2016.
The number of shares of the Company’s issued and outstanding common stock immediately following issuance of the initial Shares to the investors is 114,054,852.
Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology
An abstract of this study was presented at the 12th Annual Regional Therapies International Symposium in Snowbird, Utah in February 2017.
Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc.
Revenue for the third quarter of 2017 was $0.7 million, an increase of 75% from $0.4 million for the third quarter of 2016.
Delcath Systems Announces Medical University Of Hannover In Germany Celebrates 100th CHEMOSAT Treatment
Delcath Systems Announces Extension Of Expiration Date Of Its Consent Solicitation And Ability To Change Consent Once Voted